Targeted drug trametinib tested on rare BRAF cancers
NCT ID NCT04439279
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the drug trametinib in 35 patients with advanced cancers that have certain BRAF mutations or fusions. The goal is to see if trametinib can shrink or stop cancer growth by blocking proteins that help cancer cells grow. The study focuses on patients whose cancers have not responded to other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trametinib (Mekinist)
- What this could lead to
- If successful, this could provide a targeted treatment option for patients with certain BRAF mutations or fusions that are not covered by existing therapies.
- What could go wrong
- This is a small, early-phase trial with only 35 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects like heart rhythm issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?